Intraperitoneal paclitaxel with systemic therapy for gastrointestinal cancer with peritoneal spread
Part of Cancer, Digestive system clinical trials.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer of the stomach, esophagus/stomach junction, colon, rectum, appendix, or another digestive organ.
- Your cancer has spread to the lining of your abdomen (peritoneal carcinomatosis) and can be seen on imaging or through a procedure.
- You are 18 years or older.
- You are generally able to care for yourself (ECOG performance status 0-2), though a score of 2 is allowed if it's due to the cancer itself.
- Your organ function (kidney, liver, bone marrow) meets certain minimum levels, like blood counts and liver enzymes.
- You have not had prior repeated intraperitoneal treatments (like HIPEC, PIPAC, or NIPEC), except for a single HIPEC during surgery.
- You have no current bowel blockage (unless it's due to the cancer at the stomach outlet).
- You have no active infections or serious heart conditions (heart failure, recent stroke, heart attack, or unstable angina).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
This trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemotherapy improves outcomes for people with stomach or esophageal cancer that has spread to the lining of the abdomen (peritoneal metastasis).
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.